Latest News and Press Releases
Want to stay updated on the latest news?
-
Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90%...
-
ROCKVILLE, MD, Dec. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
-
MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibitionRecommended Phase 2 dose established for MSS CRC, NSCLC expansion...